The 10-second takeaway
For the quarter ended June 30 (Q2), GlaxoSmithKline missed estimates on revenue and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue dropped and GAAP earnings per share improved.
Gross margins dropped, operating margins dropped, and net margins grew.
GlaxoSmithKline reported revenue of $10.14 billion. The 10 analysts polled by S&P Capital IQ hoped for net sales of $10.45 billion on the same basis. GAAP reported sales were 6.1% lower than the prior-year quarter's $10.79 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.82. The one earnings estimate compiled by S&P Capital IQ predicted $0.86 per share. GAAP EPS of $0.39 for Q2 were 11% higher than the prior-year quarter's $0.35 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 69.2%, 660 basis points worse than the prior-year quarter. Operating margin was 26.9%, 240 basis points worse than the prior-year quarter. Net margin was 19.4%, 290 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $10.90 billion. On the bottom line, the average EPS estimate is $0.96.
Next year's average estimate for revenue is $42.62 billion. The average EPS estimate is $3.84.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 29 members out of 34 rating the stock outperform, and five members rating it underperform.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on GlaxoSmithKline is outperform, with an average price target of $48.52.
- Add GlaxoSmithKline to My Watchlist.